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ABSTRACT
The two leading yeast pathogens of humans, Candida albicans and Cryptococcus neoformans, 
cause systemic infections in >1.4 million patients worldwide with mortality rates approaching 
75%. It is thus imperative to study fungal virulence mechanisms, efficacy of antifungal drugs, and 
host response pathways. While this is commonly done in mammalian models, which are afflicted 
by ethical and practical concerns, invertebrate models, such as wax moth larvae and nematodes 
have been introduced over the last two decades. To complement existing invertebrate host 
models, we developed fifth instar caterpillars of the Tobacco Hornworm moth Manduca sexta as 
a novel host model. These caterpillars can be maintained at 37°C, are suitable for injections with 
defined amounts of yeast cells, and are susceptible to the most threatening yeast pathogens, 
including C. albicans, C. neoformans, C. auris, and C. glabrata. Importantly, fungal burden can be 
assessed daily throughout the course of infection in a single caterpillar’s feces and hemolymph. 
Infected caterpillars can be rescued by treatment with antifungal drugs. Notably, these animals 
are large enough for weight to provide a reliable and reproducible measure of fungal disease and 
to facilitate host tissue-specific expression analyses. M. sexta caterpillars combine a suite of 
parameters that make them suitable for the study of fungal virulence.
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Introduction
Fungal infections pose a serious threat to human health 
and well-being worldwide. Each year, as many, if not 
more patients, die of fungal infections than of malaria 
or tuberculosis [1]. The leading yeast pathogens, 
Candida albicans and Cryptococcus neoformans, 
account for ~1,400,000 life-threatening infections 
worldwide with mortality rates of up to 70% [1,2]. 
Candidemia, most frequently caused by C. albicans, is 
the fourth most common cause of nosocomial blood 
stream infections, only surpassed by infections with 
Staphylococci and Enterococcus spp. Disturbingly, can-
didemia incidence rates are on the rise. Within less 
than ten years, they increased by 36% [3]. Although 
cryptococcosis incidence rates are on the decline in 
North America, cryptococcosis as an AIDS-defining 
illness is responsible for 15% of all AIDS-related deaths 
worldwide [3,4]. This dire situation is further con-
founded by the emergence of drug-resistant yeast spe-
cies, such as C. glabrata and C. auris. Patients at risk of 
developing invasive candidemia are often prophylacti-
cally treated with fluconazole and echinocandins as 
a first line defense strategy [5]. Yet, C. glabrata, the 
most common non-albicans Candida species associated 
with nosocomial blood stream infections [6], is intrin-
sically less susceptible to azole drugs and acquires resis-
tance to echinocandins rapidly [7]. The rapid global 
spread of multidrug-resistant C. auris has further exa-
cerbated the threat posed by fungal infections. C. auris 
was first reported in 2009 in Japan [8]. In 2015, C. auris 
arrived in Europe causing an outbreak involving 72 
patients in a cardio-thoracic hospital in London [9]. 
C. auris outbreaks have been reported from South 
Korea, India, Spain, Columbia, Switzerland, Germany, 
Israel, Kuwait, and Oman [10]. Most concerningly, up 
to 25% of C. auris isolates are multidrug resistant, with 
some strains being resistant to three of the four drug 
classes available for the treatment of systemic candide-
mia. In addition to the unacceptably high burden on 
human health, fungal infections substantially increase 
health care costs. Treatment of candidemia requires 
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extended hospitalization, resulting in additional costs of 
up to 45,000 USD in adult patients or up to 119,000 
USD in pediatric patients [11].
It is thus imperative to investigate fungal virulence 
and host response mechanisms. This is traditionally 
done in mammalian models. Mice are by far the most 
frequently deployed host model. The tail vein infection 
model of candidemia, the gastrointestinal infection 
model of candidemia, the Candida vaginitis model 
[12] and the mouse inhalation model of cryptococcosis 
[13] are used extensively. While mice outnumber rab-
bits, specific aspects of fungal disease, such as chronic 
cryptococcal meningitis [14], and Candida keratitis [15] 
are often studied in rabbits. Both mammalian models 
combine a number of features that make them particu-
larly amenable for the study of fungal diseases, such as 
susceptibility, availability of knockout mutants, and 
histology comparable to human disease. Yet, using 
mammals is ethically controversial, costly, and requires 
extensive board certifications and documentation.
In an effort to reduce the usage of mammalian hosts, 
alternative invertebrate models have been developed 
and successfully used over the past two decades. The 
most commonly employed invertebrate species include 
the nematode Caenorhabditis elegans, the fly Drosophila 
melanogaster, and larvae of the Greater Wax moth 
Galleria mellonella. All three can be easily maintained 
in the laboratory, are much less expensive than mice or 
rabbits, and have been used for the study of diverse 
yeast pathogens, such as C. neoformans [16,17], 
C. albicans [17–19], C. parapsilosis [19–21], 
C. glabrata [20,22]. Of note, invertebrate models differ 
in their applicability and the best suitable model should 
be carefully selected [23]. Unlike mammalian models, 
these invertebrates do not have adaptive immunity but 
all share components of the innate immune system 
[24,25], some of which are conserved with mammals. 
This includes the Toll-like receptors found in the fly 
[26] and the homolog of the MKK3/6 kinase in the 
nematode [27]. Ironically, it is the Toll-like receptors 
that protect flies from infections with C. neoformans 
[28], C. albicans [29], and C. glabrata [30] and the 
MKK3/6 homolog SEK-1 protects the nematode from 
bacterial invaders [27]. Thus, to increase susceptibility 
of flies and nematodes to fungal pathogens, Toll and 
sek-1 [31] mutants are required. A key limitation for 
the study of human pathogens, is the inability of nema-
todes and flies to survive human body temperature. 
Only Galleria can withstand 37°C [17]. Due to their 
long-standing history as eukaryotic models, well- 
curated genomes and genome databases exist for the 
nematode and the fly. Although the Galleria genome 
has been announced recently [32], detailed analyses and 
annotations are still outstanding. Delivery of an exact 
inoculum of fungal cells is crucial when comparing 
mutant and wild-type yeast strains, neither fly nor 
nematode permit routine direct injection. Galleria can 
be directly injected with a defined cell number. 
Extensive stock collections provide fly and nematode 
strains, while until recently, Galleria larvae had to be 
purchased from fishing shops. Now, UK-based TruLarv 
is selling research grade larvae.
Tobacco Hornworms are most common in the 
southern United States, where they feed on solanaceous 
plants and are thus considered a plant pest. As an insect 
model with a long history in research, Manduca sexta 
has yielded important insights into flight mechanisms, 
nicotine resistance, hormonal regulation of develop-
ment, metamorphosis, antimicrobial defenses, and bac-
terial pathogenesis. M. sexta laboratory stocks have 
been derived from animals collected in North 
Carolina, USA [33] and have been maintained in 
laboratories on both sides of the Atlantic for several 
decades. M. sexta’s research portfolio includes a draft 
genome sequence that has been complemented with 
tissue-specific transcriptomic analyses [34], numerous 
successful applications of RNAi [35–39]. Down-stream 
analyses [40] of the animal’s innate immunity [41], 
which also comprises b-(1,3)-glucan recognition pro-
teins [41], are facilitated by protocols for the efficient 
extraction of hemocytes. Despite its versatility, M. sexta 
has yet to be explored for its suitability as a host model 
for fungal infections.
Here, we aimed to establish M. sexta as a novel 
model host for the study of fungal virulence. Inbred 
animals from the University of Bath’s research colony 
were tested for their ability to live at 37°C, their sus-
ceptibility to different yeast species, and the reproduci-
bility of C. albicans mutant phenotypes obtained in 
mice virulence studies. Indeed, the caterpillars grow at 
37°C while maintaining susceptibility to the leading 
yeast pathogens C. albicans, C. neoformans, and the 
emergent C. auris. Specific C. albicans mutants are 
just as attenuated in their virulence in M. sexta as 
they are in mice. To expand M. sexta’s applicability as 
a host model, we developed an infection protocol that 
permits screening of fungal burden throughout the 
course of infection in a single animal and uses weight 
as a proxy measure for virulence in addition to survival. 
M. sexta can furthermore be used to test efficacy of 
common antifungal drugs and to query the host tran-
scriptional response to systemic yeast infections. Our 
results define M. sexta characteristics that recommend 
these caterpillars as a nonmammalian host model for 
the study of fungal virulence with susceptibility to 
different yeast species.
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Materials and methods
Origin of the Bath colony of Manduca sexta
The University of Bath colony has been in continuous 
culture since 1978 without the addition of animals from 
elsewhere. Bath’s genetic stock was derived from ani-
mals from the Truman-Riddiford laboratories at the 
University of Washington in Seattle, USA. Their ani-
mals date back to the ones originally collected in North 
Carolina in 1976 [33]. Researchers in Europe wishing to 
obtain M. sexta caterpillars, please contact manduca@-
bath.ac.uk. Researchers in North America can purchase 
M. sexta caterpillars from the Carolina Biological 
Supply Company (item #143,882).
Caterpillar maintenance and yeast culture 
conditions
M. sexta caterpillars from Bath’s facility were reared to 
fifth instar under standardized conditions. They were 
maintained in 125 ml disposable cups (Sarstedt Ltd., 
Cat. No. 75.1335) on a wheat germ-based diet (Table S1) 
at a constant temperature of 25°C with 50% humidity and 
12 hours light/dark cycles. Three days prior to fungal 
inoculations, animals were shifted to a formaldehyde- 
free diet as formaldehyde is toxic to nonmethylotrophic 
yeast.
For infection assays, yeasts were grown overnight in 
50 ml YPD (1% yeast extract, 2% peptone, 2% dextrose) 
at 30°C and cells were harvested by centrifugation for 
3 minutes at 3,000 rpm. The cell pellet was washed 
twice with 1x phosphate buffered saline (PBS) and 
suspended in 5 ml 1x PBS. Cells were counted and 
numbers adjusted as indicated. C. albicans YSD85 
(Table 1) cells were heat-inactivated by incubation at 
65°C for 20 minutes. For long-term storage, yeasts were 
cryo-archived at −80°C in 25% glycerol.
Yeast infections and measurements of fungal 
burden and drug efficacy
100 µl of washed and number-adjusted yeast suspen-
sion were injected into each caterpillar’s distal right 
proleg with a 30G1/2” needle (BD Microlance) and 
a 1 ml NORM-JECT syringe. Following injection, 
each animal’s weight was recorded. Animals were 
scored for survival and weight once daily for three or 
four days post infection. During the course of the 
experiment, animals were kept on their regular diet 
(Table S1), on a 12-hour light/dark cycle at the tem-
perature indicated.
To measure fungal burden in caterpillar feces and 
hemolymph, six animals were injected with either 
100 µl of 1x PBS or 106 cells of the wild type SN95 
(YSD89) or the hog1∆/∆ mutant strain YSD883 (Table 
1) and kept at 37°C. On infection day (Day 0), feces and 
hemolymph were dissolved in 1x PBS and spread with-
out further dilution onto YPD. On Day 1, two animals 
were selected from each group and their hemolymph 
and feces were collected daily throughout the course of 
infection (Days 1–3). To collect hemolymph, animals 
were first kept on ice for 15 minutes. The “horn” was 
then surface sterilized with 70% ethanol and its top 
1–2 mm clipped with a pair of micro scissors. 
Hemolymph was collected in a prechilled 1.5 ml 
Eppendorf tube and cooled immediately to reduce 
polymerization and melanization. One fecal pellet was 
collected daily with sterile forceps, weighted and sus-
pended in 500 µl 1x PBS. Prior to diluting, the suspen-
sion was thoroughly vortexed for 10 seconds, and 
centrifuged for 5 seconds using a table-top centrifuge 
to separate fecal matter. To quantify fungal burden, 
hemolymph and fecal samples were plated either 
directly onto YPD-agar with 50 µg/ml Kanamycin or 
in ten-fold serial dilutions. Agar plates were incubated 
at 30°C for 48 hours and colonies counted.
To assess the efficacy of commonly used antifungal 
drugs, animals were infected with 107 cells of YSD85 
(Table 1) or 100 µl PBS and treated with increasing 
doses of fluconazole and caspofungin (Sigma Aldrich, 
Inc.) as indicated. Drugs were injected 30 minutes post-
infection with an ethanol-sterilized Hamilton syringe in 
a total volume of 10 µl per animal. Caterpillars were 
weighed and scored for survival on the day of injection 
and the following three days.
Statistical analyses
Kaplan-Meier estimators were calculated from the 
survival data using the Surv function in the “survival” 
R package [50], implementing right censoring for 
Table 1. Yeast strains used in this study.
Strain ID Strain Name (genotype) Species Source
YSD89 SN95 C. albicans 63
YSD85 SC5314 C. albicans
YSD87 BWP17 C. albicans 42
YSD190 VIC84 (cka2∆/∆) C. albicans 43
YSD192 VIC93 (cka2/cka2::CKA2) C. albicans 43
YSD302 CAS12 (ahr1∆/∆) C. albicans 65
YSD303 CAS13 (ahr1/ahr1::AHR1) C. albicans 65
YSD304 RM1000 C. albicans 44
YSD305 JC52 (hog1/hog1::HOG1) C. albicans 44
YSD306 JC50 (hog1∆/∆) C. albicans 44
YSD883 hog1∆/∆ C. albicans This study
YSD790 YPS143 S. cerevisiae 45
YSD1448 NCYC2580 M. pulcherrima 46
YSD465 2001 C. glabrata 47
YSD1454 TA004-14 C. auris 48
YSD1028 H99 C. neoformans 49
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surviving animals. Survival curves were plotted using 
the “survminer” R package [51]. Differences between 
treatments were evaluated with a log rank test com-
paring either different yeast inoculum sizes to each 
other or different drug concentrations to the vehicle 
only controls. Weight and fungal burden were plotted 
using ggplot2 [52] and weight differences were eval-
uated using linear models with day postinoculation 
and the interaction between treatment and days post 
infection as fixed effects and individual as a random 
effect using the lme function from the “nlme” 
R package [53]. The survival and weight analyses 
code can be found here: https://github.com/hobrien/ 
DiezmannLabManduca/blob/master/R/Results.Rmd. 
All analyses were conducted in R version 3.6.0.
RNA sequencing and gene expression analysis
Five animals were injected with 100 µl 1x PBS or 106 
yeast cells of the wild-type strain SN95 (YSD89) (Table 
1) and maintained on a 12-hour light/dark cycle at 37° 
C for 24 hours. Three animals were then randomly 
selected for transcriptomic analyses of their midguts. 
In preparation for midgut extraction, animals were sur-
face sterilized and midgut tissue extracted and washed 
as described before [34]. Midgut RNA was extracted 
using TRIzol reagent (Invitrogen, Inc.), quantified 
using the Agilent 2100 Bioanalyzer system and used 
to generate RNA-seq libraries (strand-specific, paired 
end) using the TruSeq RNA sample prep kit (Illumina).
150 nucleotides of the sequence were determined 
from both ends of each cDNA fragment using the 
HiSeq 2500 platform (Illumina). An average of 
83.79 million read pairs were obtained for each sample 
(range: 51.4 M to 109.8 M read pairs). Sequencing reads 
were aligned to a combination of the Manduca sexta 
whole genome assembly v1.0 (https://i5k.nal.usda.gov/ 
Manduca_sexta) and the Candida albicans SC5314 gen-
ome version 4 (http://fungi.ensembl.org/Candida_albi 
cans_sc5314_gca_000784635) using HISAT2 [54]. 
HTSeq [55] was used to generate read counts for each 
gene. RNAseq data are available at NCBI’s Short Read 
Archive (PRJNA629104).
Statistical analysis of differential gene expression was 
performed using the DEseq2 package from 
Bioconductor [56] and the SARTools pipeline [57]. 
A gene was considered differentially expressed if the 
FDR-value for differential expression was less than 
0.10. A heatmap of all differentially expressed genes 
was made using the heatmap.2 function from the 
“gplots” R package [58].
In order to compare the M. sexta transcriptional 
response to C. albicans infection by to that of 
a mouse, we generated a blast reference database 
using the peptide sequences for 67,960 proteins from 
the mouse genome (GRCm38) available from Ensembl 
(https://useast.ensembl.org). We downloaded the pep-
tide sequences for 27,403 proteins from the M. sexta 
database [34]. We computed peptide sequence similar-
ity between the M. sexta proteins and the mouse pro-
teins using the blastp local alignment search tool (ncbi- 
blast+ v2.8.1) [59]. For each M. sexta protein, we had 
multiple hits that were ranked based on the e-value 
computed by the blastp search tool. For the list of 
differentially expressed M. sexta genes from each com-
parison, we extracted the mouse orthologs with 
e-values smaller than 10−20. This list of orthologs was 
then compared to differential expression lists based on 
RNA-seq analysis of kidneys [60], tongues [61], and 
vaginas [62] from C. albicans infected mice. Gene lists 
were compared using VennDiagram (https://cran.r-pro 
j e c t . o r g / w e b / p a c k a g e s / V e n n D i a g r a m / V e n n  
Diagram.pdf).
Results
M. sexta caterpillars are susceptible to the leading 
fungal pathogen C. albicans at 37°C
We first aimed to determine if M. sexta fifth instar 
caterpillars (Figure 1(a)), reared and maintained at 
standard conditions, are susceptible to C. albicans. To 
do so, groups of ten animals were infected with increas-
ing doses of the widely used C. albicans laboratory 
strains SC5314 and SN95 [63] (Table 1). Animals 
were kept at 25°C, their standard maintenance tem-
perature, and scored for survival on three consecutive 
days. Dead animals go limp and turn brown-green in 
color, which is in stark contrast to the vivid turquoise 
of live animals (Figure 1(b)). Caterpillars infected with 
C. albicans succumbed in a dose-dependent manner. 
Both C. albicans strains killed M. sexta efficiently at 
inocula of 106 or 107 cells per animal (Figure 1(c)). To 
assess if survival measures in caterpillars are compar-
able to those obtained in the current gold standard, the 
murine model of systemic candidemia, we tested 
C. albicans mutants with published phenotypes of 
either attenuated virulence, such as the hog1∆/∆[64] 
and ahr1∆/∆[65] mutants, or wild-type levels of viru-
lence, such as cka2∆/∆[66] (Table 1). Hog1 is just as 
essential for virulence in caterpillars as it is in mice. 
Cka2 is not required to establish systemic infections in 
mammals but is in caterpillars. Ahr1, while required for 
virulence in mammals, appears to be dispensable for 
virulence in caterpillars (Figure 1(d)).
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Given the importance of temperature for fungal viru-
lence, we investigated if M. sexta retained their suscept-
ibility to C. albicans at human body temperature. We first 
aimed to establish the effect of raising the temperature 
from 25°C to 37°C on uninfected caterpillars’ survival and 
development. All animals survive four-day exposure to 
37°C but grow slower than at 25°C (p = 0.0001) (Fig. S1). 
Next, we quantified survival of animals infected with 
C. albicans wild type at 37°C (Figure 2(a)). 
105 C. albicans cells elicit 50% mortality on Day 2, while 
106 C. albicans cells lead to 100% mortality on Day 3. In 
comparison, 107 cells are required for the same outcome 
at 25°C (Figure 1(b)). Increased susceptibility at 37°C may 
be due to the temperature-dependent expression of 
C. albicans virulence traits, such as the yeast-to-hyphae 
transition, which is triggered at 37°C. To exclude the 
possibility that mortality is due to starvation rather than 
the outcome of a host-pathogen interaction, we infected 
caterpillars with live and heat-killed C. albicans wild-type 
cells and measured survival and weight at 37°C. Only live 
cells, but not heat-killed yeast cells, kill caterpillars sug-
gesting that killing is not due to nutritional limitations 
(Fig. S2a). Weight gain, however, was larger in caterpillars 
injected with heat-killed Candida cells than PBS, indicat-
ing that dead yeast cells may be of nutritional value to 
M. sexta (p < 0.0001) (Fig. S2b).
Demonstrating susceptibility of M. sexta caterpillars to 
C. albicans lent support to their suitability as an 
Figure 1. M. sexta caterpillars are susceptible to infections with C. albicans at their standard maintenance temperature of 25°C. (a) 
13-day old M. sexta fifth instar caterpillar prior to injection, weighing ~2 g. Its distinguishing feature, the reddish horn at the 
posterior, is clearly visible. (b) 24 hours post injection with the C. albicans wild-type strain SC5314, the dead animal on the left has 
lost color and turgidity compared to the live PBS control animal on the right. (c) Groups of 10 animals were infected with C. albicans 
SN95 or SC5314 wild-type strains. Kaplan-Meier curves show dose-dependent killing of caterpillars as indicated by the inset p-values 
for overall differences, excluding PBS controls. (d) Survival curves of 10 animals per group infected with 107 cells of C. albicans 
mutants that have attenuated virulence phenotypes in mice or epithelial cell models. The hog1∆/∆ and cka2∆/∆ mutants exhibit 
attenuated virulence, while virulence of the ahr1∆/∆ mutant is comparable to wild type. The hog1∆/∆ mutant differs significantly 
from the wild type (p = 0.0001), while the complemented strain hog1/hog1::HOG1 kills M. sexta at a level comparable to that of the 
wild-type strain (p = 0.21). The cka2∆/∆ mutant is significantly less virulent than the wild type (p = 0.00021), while the 
complemented strain cka2/cka2::CKA2 is not (p = 0.054). Shown is one of two comparable biological replicates.
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alternative host model for the study of fungal virulence 
and emphasized the need for additional measures of fun-
gal virulence. To add granularity to fungal virulence data 
collected from M. sexta, we complemented measures of 
survival with quantifications of weight. To collect weight 
data, caterpillars were weighed prior to infection and then 
daily. Weight gain in animals infected with a low dose of 
104 cells did not significantly differ from those injected 
with 1x PBS (p = 0.5847) but caterpillars infected with105 
cells per animal exhibited significant weight loss 
(p = 0.0001). Too few animals survived infection with 
106 cells to allow for a meaningful comparison (Figure 2 
(b)). After establishing susceptibility of M. sexta to 
C. albicans at 37°C, we aimed to validate the attenuated 
virulence phenotype of the hog1∆/∆ mutant strain. To test 
this, caterpillars were infected with 106 cells of the wild- 
type strain, the hog1∆/∆ deletion mutant, and the hog1/ 
hog1::HOG1 complementation strain (Table 1). Virulence 
in the hog1∆/∆ mutant is significantly attenuated at 37°C 
(Figure 2(c)). Weight gain was larger in animals infected 
with the hog1∆/∆ mutant strain than those infected with 
the wild-type strain (p < 0.0001), while infection with the 
complemented strain lead to a comparable lack in weight 
gain as in wild type infected animals (Figure 2(d)).
Measurements of fungal burden in feces and 
hemolymph obtained from a single animal 
throughout infection provides a useful measure of 
virulence
To further expand the applicability of M. sexta cater-
pillars as a host model for fungal infections, fungal 
burden in the hemolymph and feces was quantified 
daily throughout the course of infection. Since the 
Figure 2. Elevated temperature increases susceptibility of M. sexta to C. albicans. Groups of 10 animals were injected with increasing 
doses of the C. albicans wild-type strain SC5314 or with 106 cells of the hog1∆/∆ mutant strain and its complemented control and 
wild-type progenitor and kept at 37°C for the duration of the experiment. (a) M. sexta caterpillars succumb to infection with 105 cells 
of the laboratory strain SC5314 at 37°C. (b) Weight gain of caterpillars infected with C. albicans was significantly reduced at all doses 
relative to PBS controls (**** = P < 0.0001). (c) Attenuated virulence of the hog1∆/∆ mutant is retained at 37°C. (d) Animals infected 
with the hog1∆/∆ mutant gain significantly more weight than those infected with the wild-type strain RM1000 (**** = P < 0.0001). 
Infection with the hog1/hog1::HOG1 complemented strain resulted in a lack of weight gain comparable to wild type (p = 0.16). 
Shown is one of two comparable replicates.
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collection of hemolymph or feces does not necessitate 
killing the animal, data could be collected daily through-
out the course of infection for the same caterpillar. 
Animals infected with the wild type and the hog1∆/∆ 
mutant (Table 1) were compared to control animals 
injected with 1x PBS only and fungal burden measured 
as colony-forming units (CFUs) in feces and hemo-
lymph in two animals per group. Yeasts were detected 
in the feces and hemolymph of animals infected with the 
wild type on Day 2 and CFU counts increased on Day 3 
(Figure 3(a,b)). In animals infected with the hog1∆/∆ 
mutant, low CFU counts were detected on Day 3 in 
feces and hemolymph. Even fewer CFUs were detected 
in the hemolymph of animals injected with PBS on Day 
3. Weight measures showed an inverse correlation 
growth of the pathogen and the host for the 
C. albicans wild-type strain (Fig. S3). Thus, measure-
ments of fungal burden, that can be obtained from the 
same animal throughout the course of infection, provide 
a valuable parameter for the study of fungal virulence.
Caterpillars are suitable for antifungal drug 
treatment studies
The currently available armamentarium of antifungal 
drugs is limited and the drugs that are available are 
often lacking in efficacy. Abilities to study drug efficacy 
and mode of action in a host model are thus pertinent 
to the development of novel antifungal drugs. To deter-
mine M. sexta’s suitability for drug efficacy testing, we 
recorded survival and weight of animals infected with 
the C. albicans wild-type strain SC5314 (Table 1) that 
were treated with increasing doses of two common 
antifungals, fluconazole and caspofungin (Figure 4). 
Treatment with the echinocandin caspofungin signifi-
cantly improves caterpillar survival (p = 4x10−4) and 
weight gain (p = 0.0047) when compared to untreated 
animals (Figure 4(a,b)). Doses of 2 mg/kg (p = 0.01) 
and 4 mg/kg (p = 0.002) are most effective in improv-
ing survival. Treating animals with fluconazole 
improves survival rates but caterpillars still grow slower 
(Figure 4(c,d)). Thus treatment with antifungals cures 
caterpillars from fungal disease.
M. sexta caterpillars are broadly susceptible to 
different yeast pathogens
While C. albicans is undoubtedly a major fungal patho-
gen of humans, clinical manifestations of fungal infec-
tions are not limited to C. albicans. To broaden 
M. sexta’s applicability, we sought to quantify the cater-
pillars’ susceptibility to other fungal pathogens. To this 
Figure 3. Fungal burden in caterpillar feces and hemolymph as a measure of disease progression. Six animals were injected with 
either 100 µl 1x PBS or 106 cells of the wild-type strain SN95 or its hog1∆/∆ derivative (YSD883) and maintained at 37°C. On Day 1, 
two surviving animals were selected from each group for CFU analysis. Colony forming units per gram feces (a) and 100 µl 
hemolymph (b) increase in the wild-type strain between Day 2 and 3 but are not detectable in the hog1∆/∆ mutant nor the control 
animals until Day 3. Each CFU data point represents the average of at least two (usually three to four) technical replicates.
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end, animals were infected with wild-type strains of 
C. neoformans, C. auris, and C. glabrata (Table 1). Type 
strains of Saccharomyces cerevisiae, the baker’s or 
brewer’s yeast and Metschnikowia pulcherrima (Table 
1), a yeast inhabiting fruits and flowers [67], served as 
reference points for species with attenuated virulence. 
Based on our initial C. albicans infection assays (Figure 
2), animals were infected with increasing doses of yeast 
cells starting at 105 cells per animal and up to 109 cells 
per animal and maintained at 37°C. Groups of ten ani-
mals per yeast dose and species were then screened for 
survival and weight daily (Figures 5 and 6). Notably, only 
infections with pathogenic yeast species affected survival 
of caterpillars (Figure 5). Infections with S. cerevisiae or 
M. pulcherrima barely affected caterpillar survival. 
Comparing survival amongst the pathogenic yeast spe-
cies revealed C. albicans to be the most severe. 
107 C. albicans cells result in 100% killing within in 
one day. 109 C. auris cells were required to kill all animals 
within four days and the same dose of C. glabrata 
resulted in 75% killing. 108 C. neoformans cells were 
required to achieve 50% killing within four days, com-
parable to C. glabrata. It should be noted that due to the 
high viscosity of the cell suspension, we could not test 
higher concentrations than the ones stated here. In addi-
tion to assessing survival, each surviving caterpillar’s 
weight was recorded daily.
Interestingly, S. cerevisiae and M. pulcherrima did 
not kill caterpillars as effectively as clinical species, yet, 
animals infected with S. cerevisiae did not gain weight 
as well as uninfected control animals (Figure 6). This is 
in contrast to animals infected with the C. albicans 
hog1∆/∆ mutant whose weight gain was significantly 
different from wild type infected caterpillars (Figure 2). 
Infections with C. albicans resulted in severely reduced 
weight gain, even at the lowest yeast dose tested, while 
Figure 4. Antifungal efficacy testing of fluconazole and caspofungin. Groups of ten caterpillars infected with 106 cells of C. albicans strain 
SC5314 were treated with increasing doses of antifungal drugs fluconazole or caspofungin and maintained at 37°C for the duration of the 
experiment. Differences between drug treatments were evaluated using a log rank test comparing animals injected with different amounts of 
drug to those injected with drug solvent (water or DMSO) only, excluding PBS injection controls. Weight gain was compared to the PBS control 
due to low survival in the solvent control group. (a) Animals were scored daily for survival showing survival improved significantly in animals 
receiving caspofungin treatment. Inset p value relative to drug solvent control. (b) Rate of weight gain, however, remains low (p < 0.0001) for 
animals that received 2 or 4 mg/kg caspofungin. The peak and drop in weight, marked with a �, is coinciding with the onset of prepupation. 
This “pupation drop” is due to the animals refraining from food upon entering the early stages of pupation. (c) Fluconazole treatment improves 
M. sexta survival but weight gain remains low compared to PBS control infected animals (p < 0.005) for all treatments. (d) Weight data were not 
analyzed for significance due to the lack of surviving animals in the no treatment group.
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only the highest dose of C. auris elicited a significant 
reduction in weight gain. C. glabrata infection signifi-
cantly reduced weight gain at the lowest dose but only 
slightly at higher doses. Infections with C. neoformans 
resulted in significantly reduced weight gain at all but 
the lowest concentration tested. Caterpillars displayed 
variable degrees of susceptibility to different yeast 
pathogens and with weight providing an additional 
measure of host damage. Thus, M. sexta caterpillars 
are broadly applicable for the study of fungal virulence.
M. sexta transcriptional response profiles differ 
between uninfected and infected animals
As a proof-of-concept we recorded transcriptional pro-
files in three animals infected with the wild-type strain 
SN95 (Table 1) and compared them to three uninfected 
control animals. To do so, we collected the mid-gut, 
rinsed the tissue thoroughly, and extracted RNA, which 
was then sequenced using Illumina’ HiSeq 2500 plat-
form. With the vast majority of reads mapping to 
M. sexta rather than C. albicans (Fig. S4), animals 
infected with Candida displayed a transcriptional pro-
file different from that of uninfected animals (Fig. S5, 
Table S2). Infection with the wild type elicited quantifi-
able transcriptional changes in the caterpillars. 
157 M. sexta genes were up-regulated and 165 went 
down when compared to the PBS control animals 
(Table S2).
Lastly, we compared our set of differentially 
expressed M. sexta genes to those identified in three 
murine candidemia studies. Here, tissue-specific 
responses in the kidneys [60], tongues [61], and vaginas 
[62] were recorded for animals infected with Candida 
Figure 5. Caterpillars are susceptible to common yeast pathogens. Groups of ten animals were infected with increasing numbers of 
yeast cells as specified and survival was recorded daily. Inset p values represent results from a log rank test of all treatments 
excluding PBS. Caterpillars are not susceptible to S. cerevisiae or M. pulcherrima but infections with C. neoformans, C. glabrata, 
C. auris, and C. albicans result in significantly reduced survival rates.
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wild type (Figure 7, Table S3). M. sexta genes up- 
regulated during infection and their homologs in all 
three mouse tissues include serine peptidase inhibitors 
(Serpinb3 c, Serpinb3b), a Ras-like protein (Rit2), 
transmembrane proteases (Tmprss11a, Tmprss11 f), 
a histidine decarboxylase (Hdc), and a peptidoglycan 
recognition protein (Pglyrp3). M. sexta genes down- 
regulated in mouse kidney and vagina include 
a muscle glycogen phosphorylase (Pygm), a bone mor-
phogenetic antagonist of the DAN family (Grem1), 
meprin 1 alpha (Mep1a), and calponin 1 (Cnn1). Two 
of these genes are annotated as functioning in immune 
system processes (Grem1, Pglyrp3) and three more are 
relevant for signaling and response to different stimuli 
(Rit2, Pglyrp3, Pygm). Seven genes, however, are 
involved in protein metabolic processes (Serpinb3 c, 
Serpinb3b, Rit2, Tmprss11a, Tmprss11 f, Grem1, 
Mep1a), suggesting this fundamental process to be of 
importance in the defense against microbial attacks.
Discussion
Invertebrate host models have become valuable alter-
natives to mammalian hosts for the study of fungal 
disease. Here, we developed M. sexta caterpillars as 
a novel invertebrate model showing that they are 
Figure 6. Caterpillar weight as a measure of virulence. Groups of ten animals were infected with increasing amounts of yeast inocula 
from six different species or PBS and the weight of surviving animals was recorded daily. Weight measures of yeast-infected 
caterpillars were analyzed for statistical significance revealing that yeast infections affect weight regardless of mortality rates. The 
slope of each curve at each yeast concentration was compared to the PBS control by fitting a mixed model where caterpillars were 
treated as a random effect using linear mixed-effects modeling. Statistical significance was assessed as follows: * p < 0.05, ** 
p < 0.01, *** p < 0.001, **** p < 0.0001.
1084 N. LYONS ET AL.
naturally susceptible to different human pathogenic 
yeast species, including the emergent multidrug- 
resistant C. auris. Unlike other host models, these 
large caterpillars permit daily measures of fungal bur-
den throughout the course of infection in a single ani-
mal by either collecting feces or hemolymph. M. sexta 
can be maintained at 37°C, is large enough to be 
injected with a specified yeast inoculum and for weight 
to be a reliable measure of virulence. C. albicans mutant 
virulence phenotypes found in mice can be replicated 
and yeast inocula required to elicit a response in cater-
pillars are comparable to those used in the murine 
model. Additionally, the caterpillars permit study of 
antifungal drug efficacy. While these parameters com-
mend M. sexta as a novel host model for the study of 
fungal virulence, a couple of caveats should be noted. 
Firstly, as with all animal models, their development 
follows strict rules. The caterpillars will conclude their 
fifth instar stadium within 4–5 days, possibly limiting 
their suitability for some assays. This time span, how-
ever, is comparable to the leading insect model, 
G. mellonella, which has successfully been used for 
antifungal drug evaluations [68], antibacterial testing 
[69], and testing of gemini surfactants active against 
C. albicans [70]. Secondly, about 10% of infected ani-
mals exhibited normal growth and survival. It is cur-
rently unclear if this is a limitation of the infection 
protocol or something to do with the underlying biol-
ogy of the animals. This will need to be factored in 
when determining sample sizes for future experiments.
This new model system allows for fungal burden 
to be monitored throughout the course of infection 
in a single animal via CFU count. This is unlike any 
other experimental system, where fungal burden is 
either an endpoint measure in the mouse kidney, in 
homogenized wax moth larvae [71], nematodes [72], 
flies [73], or requires genetically modified fluores-
cent yeast strains for microscopic imaging and ana-
lyses [74]. While we did detect very low CFU counts 
in the PBS control 3 days post infection, we con-
sider this a spurious finding due to cross contam-
ination as preliminary experiments of plating 
contents of hemolymph and feces of naïve animals 
did not detect any yeast growth (data not shown). 
As a consequence, we amended the protocol to 
include changing gloves when handling animals of 
different treatment groups.
When reviewing the weight data collected as part of 
our study, we noticed that while S. cerevisiae has very 
little effect on caterpillar survival, infections with 
S. cerevisiae led to reduced caterpillar weight gain. 
A similar, albeit weaker, pattern was observed for infec-
tions with the fruit yeast M. pulcherrima. The dichot-
omy between survival and weight observed here further 
emphasizes that fungal virulence comprises more than 
a measure of survival. It appears that M. sexta would 
allow discrimination between disease (weight) and 
death (survival) quantitatively adding further granular-
ity to measuring fungal virulence.
Heat-killed C. albicans cells appear to be nonpatho-
genic in M. sexta caterpillars. The lack of mortality in 
response to inoculation with heat-killed yeast cells indi-
cates that yeast viability and proliferation are required 
for pathogenesis and excludes the possibility of death 
Figure 7. Mouse homologs of M. sexta differentially expressed genes. Numbers of Manduca genes and their murine homologs that 
were up- or downregulated in mouse vagina, kidney, or tongue and the overlap between the different data sets as depicted in 
a Euler diagram. Note, in some cases the same mouse gene was the best BLAST match for several M. sexta genes.
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due to an allergic reaction in response to a large num-
ber of fungal cells. This appears to differ from the 
responses of other host models to fungal pathogens. 
While susceptibility was reduced, but still measurable, 
in G. mellonella [75] and the two-spotted cricket [76], 
heat-killed C. albicans cells elicited 100% mortality in 
a sepsis-like murine model [77]. In mice, serum levels 
of β-(1,3)-glucan were elevated in animals injected with 
heat-killed yeasts when compared to those infected 
with live cells. Indeed, heat inactivation leads to 
increased exposure of β-(1,3)-glucan on the 
C. albicans cell surface [78] and β-(1,3)-glucan activates 
the innate immune response in invertebrates and mam-
mals [79]. M. sexta’s innate immunity includes a β- 
(1,3)-glucan recognition protein recognizing 
S. cerevisiae, which is expressed in the fat body and 
secreted into the hemolymph [80,81] as well as the 
antifungal molecule diapausin-1, whose expression is 
developmentally regulated [82]. The lack of response 
observed here could be due to insufficient expression of 
either protein or suboptimal exposure of β-(1,3)-glucan 
in our heat-killed C. albicans cells.
Measures of the host transcriptional response pro-
vide useful insights into the relevance of specific 
defense mechanisms. Mouse transcriptional profiles in 
response to C. albicans infections differ between differ-
ent types of tissues [60–62], which allowed for the 
identification of tissue-specific response mechanisms 
such as IL-17 signaling in oral epithelia. Here, we 
detected numerous differentially expressed genes in 
the caterpillar midgut when comparing animals 
infected with C. albicans to the PBS control. Given 
the size of M. sexta caterpillars, which permits tissue- 
specific transcriptional analyses [34], this phenomenon 
could be systematically investigated in caterpillars 
rather than mammalian hosts, who are burdened by 
ethic concerns and economic challenges prohibiting 
large scale or time-course studies. Furthermore, partial 
conservation of the transcriptional response to 
C. albicans infections between insects and mammals 
offers the opportunity to identify and investigate core 
eukaryotic response mechanisms.
In summary, Manduca sexta caterpillars expand the 
current repertoire of invertebrate models for the study 
of fungal disease. They combine a suite of measures 
that commend it as a new model system. Although, 
M. sexta genomic and transcriptomic analyses are cur-
rently still in their infancy, we would expect that the 
Tobacco Hornworm’s long history of being an invalu-
able model for diverse facets of biology will lead to 
reliable tools in combination with genetic tractability 
and protocols establishing the fungus’ fate inside the 
caterpillar.
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